Related Experiment Video

Updated: Jun 21, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity

Simak Ali1, Dean A Heathcote, Sebastian H B Kroll

  • 1Department of Oncology and Chemistry, Imperial College London, London, United Kingdom. simak.ali@imperial.ac.uk

Cancer Research
|July 30, 2009
PubMed

Insights

A novel compound, BS-181, selectively inhibits cyclin-dependent kinase 7 (CDK7), a key regulator of cell cycle progression and transcription. This potent CDK7 inhibitor demonstrates significant anticancer activity in vitro and in vivo, offering a promising new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Cell cycle progression relies on cyclin-dependent kinases (CDKs), whose deregulation is common in cancer.
  • CDK-activating kinase (CAK) phosphorylates and activates CDKs, making it a critical regulator and therapeutic target.
  • CDK7, a component of TFIIH, regulates both cell cycle and transcription, presenting a dual target for cancer therapy.

Purpose of the Study:

  • To identify and characterize potent and selective inhibitors of CDK7 for anticancer drug development.
  • To evaluate the therapeutic potential of a novel pyrazolo[1,5-a]pyrimidine derivative, BS-181, as a CDK7 inhibitor.

Main Methods:

  • Computer modeling was employed to design potential CDK7 inhibitors.
  • In vitro kinase assays were performed to determine the inhibitory activity (IC50) of BS-181 against CDK7 and other kinases.
  • Cell-based assays assessed BS-181's effects on cell cycle, apoptosis, and cancer cell line growth.
  • In vivo studies evaluated BS-181's antitumor efficacy and pharmacokinetic properties in mouse xenograft models.

Main Results:

  • BS-181 demonstrated potent inhibition of CDK7 with an IC50 of 21 nmol/L.
  • BS-181 exhibited high selectivity, with minimal inhibition of other CDKs and kinases at relevant concentrations.
  • In cancer cells, BS-181 effectively inhibited CDK7 substrate phosphorylation, induced cell cycle arrest and apoptosis, and suppressed tumor growth.
  • BS-181 showed favorable stability and antitumor effects in vivo, inhibiting xenograft growth in mice.

Conclusions:

  • BS-181 is a potent and selective inhibitor of CDK7.
  • BS-181 exhibits promising anticancer activity through cell cycle regulation and apoptosis induction.
  • BS-181 represents a potential novel therapeutic agent for cancer treatment.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...